Triple treatment combo works best for UDCA-resistant PBC: Study
A triple treatment combination adding fibrates — a type of medication that has shown promise in primary biliary cholangitis (PBC) — to dual therapy…
Cholangitis
CM-101 shows signs of targeting all PSC aspects in Phase 2 trial
The experimental therapy CM-101 is generally safe and results in signs of improvement in liver health and health of the ducts that transport the…
EMA committee recommends Iqirvo approval for PBC in Europe
A European Medicines Agency (EMA) committee has recommended the approval of Ipsen‘s Iqirvo (elafibranor) as a second-line therapy for adults with primary biliary…
NGM Bio raises funds to launch clinical trial of aldafermin for PSC
NGM Biopharmaceuticals has raised $122 million in financing, which the California-based company will use to help launch a planned registrational clinical trial to test…
PSC treatment bexotegrast safe, eases liver scarring in early trial
Six months of treatment with a high dose of bexotegrast, Pliant Therapeutics’ oral candidate, was superior to a placebo at reducing markers of disease…
PSC may increase ulcerative colitis risk, but not Crohn’s disease
Genetic variations that predispose people toward developing primary sclerosing cholangitis (PSC) are significantly associated with a higher risk of ulcerative colitis, a primary type…
More studies support use of CM-101 antibody therapy now in PSC trial
High levels of CCL24, the protein targeted by Chemomab Therapeutics’ investigational antibody-based therapy CM-101, are associated with biological pathways contributing to the progression of…
Volixibat shows early promise for reducing PBC itching, fatigue: Data
Daily treatment with Mirum Pharmaceuticals’ oral candidate volixibat significantly reduced itching — medically known as pruritus — and fatigue for adults with primary…
Seladelpar still eases itch, liver damage after 2 years: PBC trial
Two years of treatment with seladelpar, Gilead Sciences’ oral candidate, safely results in rapid and sustained reductions in itching and liver damage markers for…
Elafibranor, now Iqirvo, wins FDA accelerated approval for PBC
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ipsen’s elafibranor as a second-line treatment for primary biliary cholangitis (PBC).
Recent Posts
- Abnormal amino acid profile seen in biliary atresia infants after birth
- Our daughter’s PFIC diagnosis made us rethink drinking at Christmas
- Hepatitis D treatment combo granted new designations in US, EU
- Committee recommends seladelpar approval in EU for treating PBC
- Diet rich in omega-3 fatty acids may lower risk of ICP, scientists say